Representative George Whitesides (D-California) recently sold shares of Medtronic plc (NYSE:MDT). In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $50,001 and $100,000 in Medtronic stock on March 24th. The trade occurred in the Representative’s “GEORGE WHITESIDES INDIVIDUAL” account.
Representative George Whitesides also recently made the following trade(s):
- Sold $100,001 – $250,000 in shares of Netflix (NASDAQ:NFLX) on 3/27/2025.
- Sold $250,001 – $500,000 in shares of Innoviva (NASDAQ:INVA) on 3/25/2025.
- Sold $50,001 – $100,000 in shares of Union Pacific (NYSE:UNP) on 3/24/2025.
- Sold $100,001 – $250,000 in shares of Linde (NASDAQ:LIN) on 3/24/2025.
- Sold $100,001 – $250,000 in shares of Procter & Gamble (NYSE:PG) on 3/24/2025.
- Sold $1,001 – $15,000 in shares of Sandoz Group (OTCMKTS:SDZNY) on 3/24/2025.
- Sold $15,001 – $50,000 in shares of American Electric Power (NASDAQ:AEP) on 3/24/2025.
- Sold $100,001 – $250,000 in shares of McDonald’s (NYSE:MCD) on 3/24/2025.
- Sold $15,001 – $50,000 in shares of Bank of America (NYSE:BAC) on 3/24/2025.
- Sold $15,001 – $50,000 in shares of Diageo (NYSE:DEO) on 3/24/2025.
Medtronic Stock Down 0.1 %
Shares of NYSE MDT opened at $84.19 on Friday. The stock has a market capitalization of $107.98 billion, a PE ratio of 25.59, a P/E/G ratio of 2.22 and a beta of 0.79. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average of $88.14 and a 200-day moving average of $87.27. Medtronic plc has a 52-week low of $75.96 and a 52-week high of $96.25.
Medtronic Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were issued a $0.70 dividend. The ex-dividend date was Friday, March 28th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.33%. Medtronic’s dividend payout ratio (DPR) is presently 85.11%.
Hedge Funds Weigh In On Medtronic
A number of institutional investors have recently made changes to their positions in MDT. MONECO Advisors LLC raised its holdings in Medtronic by 1.8% in the fourth quarter. MONECO Advisors LLC now owns 6,408 shares of the medical technology company’s stock valued at $512,000 after acquiring an additional 115 shares in the last quarter. OLD Second National Bank of Aurora raised its stake in shares of Medtronic by 0.3% in the 4th quarter. OLD Second National Bank of Aurora now owns 36,303 shares of the medical technology company’s stock valued at $2,900,000 after purchasing an additional 121 shares in the last quarter. Dunhill Financial LLC lifted its position in shares of Medtronic by 17.2% during the first quarter. Dunhill Financial LLC now owns 847 shares of the medical technology company’s stock worth $76,000 after purchasing an additional 124 shares during the last quarter. Petros Family Wealth LLC lifted its position in shares of Medtronic by 4.3% during the first quarter. Petros Family Wealth LLC now owns 3,111 shares of the medical technology company’s stock worth $280,000 after purchasing an additional 127 shares during the last quarter. Finally, McKinley Carter Wealth Services Inc. grew its stake in Medtronic by 0.7% in the fourth quarter. McKinley Carter Wealth Services Inc. now owns 19,677 shares of the medical technology company’s stock worth $1,572,000 after purchasing an additional 129 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on MDT shares. Citigroup raised shares of Medtronic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $92.00 to $107.00 in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $105.00 price target on shares of Medtronic in a research report on Wednesday, February 19th. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Wednesday, February 19th. Robert W. Baird upped their target price on Medtronic from $90.00 to $91.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Finally, Truist Financial lowered their target price on Medtronic from $93.00 to $90.00 and set a “hold” rating for the company in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $96.14.
Check Out Our Latest Stock Report on MDT
About Representative Whitesides
George Whitesides (Democratic Party) is a member of the U.S. House, representing California’s 27th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Whitesides (Democratic Party) ran for election to the U.S. House to represent California’s 27th Congressional District. He won in the general election on November 5, 2024.
George Whitesides earned a bachelor’s degree in public and international affairs from Princeton University in 1996 and a master’s degree in remote sensing and GIS from the University of Cambridge in 2000. His career experience includes working as the chief of staff for NASA during the administration of President Barack Obama (D) and the CEO of human spaceflight company Virgin Galactic. Whitesides co-founded Megafire Action, an organization dedicated to responding to wildfires. Whitesides co-chaired the Antelope Valley Covid-19 Task Force and joined the Antelope Valley Economic Development and Growth Enterprise (AV EDGE) as a board member.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read More
- Five stocks we like better than Medtronic
- Find and Profitably Trade Stocks at 52-Week Lows
- Short Sellers Gave Up on These 3 Names Recently
- Quiet Period Expirations Explained
- 3 Boring Stocks Outperforming the Market This Year
- Airline Stocks – Top Airline Stocks to Buy Now
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.